Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 5/20 | 0.56 |
| ▸ | MMP8 | P22894 | 6/20 | 0.42 |
| ▸ | MMP12 | P39900 | 4/20 | 0.42 |
| ▸ | MMP13 | P45452 | 4/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256301 | 1.00 | FKBP1A (0.56) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL6830972 | 0.98 | FKBP1A (0.58) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL6830973 | 0.98 | FKBP1A (0.58) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL26212073 | 0.95 | FKBP1A (0.51) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL6831371 | 0.94 | FKBP1A (0.54) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL6831374 | 0.94 | FKBP1A (0.54) | FKBP1AMMP8MMP12MMP13MMP1 | |
| Hydroxyamine SCHEMBL5894442 | 0.93 | FKBP1A (0.50) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL10815653 | 0.92 | FKBP1A (0.48) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL9103345 | 0.89 | FKBP1A (0.47) | FKBP1AMMP8MMP12MMP13MMP1 | |
| SCHEMBL9103351 | 0.89 | FKBP1A (0.47) | FKBP1AMMP8MMP12MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927355-B2 | Method for producing an organosilicon product | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-02-23 | — | — | US | disclosed |
| US-20180371430-A1 | Heme Protein Catalysts for Carbon-Silicon Bond Formation In Vitro and In Vivo | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-12-27 | — | — | US | disclosed |
| US-10093906-B2 | Cytochrome C protein variants for catalyzing carbon-silicon bond formation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2017136466-A1 | HEME PROTEIN CATALYSTS FOR CARBON-SILICON BOND FORMATION IN VITRO AND IN VIVO | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170218346-A1 | Heme Protein Catalysts for Carbon-Silicon Bond Formation In Vitro and In Vivo | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-08-03 | — | — | US | disclosed |
| US-20100197514-A1 | PROTEIN CRYSTAL OF HUMAN CYTOCHROME P450 AROMATASE AND USES THEREOF | HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7687252-B2 | Protein crystal of human cytochrome P450 aromatase and uses thereof | Hauptman-Woodward Medcial Research Institute, Inc. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090204378-A1 | PROTEIN CRYSTAL OF HUMAN CYTOCHROME P450 AROMATASE AND USES THEREOF | HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2009061859-A2 | PROTEIN CRYSTAL OF HUMAN CYTOCHROME P450 AROMATASE AND USES THEREOF | HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-7385064-B1 | Catalysts for use in enantioselective synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-06-10 | — | — | US | disclosed |
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6433185-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
| US-6313120-B1 | TREATMENT OR PREVENTION OF DISEASES INVOLVING BRADYKININ RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-0877737-B1 | NOVEL N-(ARYLSULPHONYL)AMINO ACID DERIVATIVES HAVING BRADYKININ RECEPTOR AFFINITY | SANOFI SYNTHELABO (FR) | 2001-08-01 | — | — | EP | disclosed |
| US-6100278-A | COMPOUNDS HAVING AFFINITY FOR BRADYKININ RECEPTORS; ANTIINFLAMMATORY AGENTS | SANOFI-SYNTHELABO (FR) | 2000-08-08 | — | — | US | disclosed |
| US-6015812-A | N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity | SANOFI-SYNTHELABO (FR) | 2000-01-18 | — | — | US | disclosed |
| EP-0877737-A1 | NOVEL N-(ARYLSULPHONYL)AMINO ACID DERIVATIVES HAVING BRADYKININ RECEPTOR AFFINITY | SANOFI (FR) | 1998-11-18 | — | — | EP | disclosed |
| WO-1997025315-A1 | NOVEL N-(ARYLSULPHONYL)AMINO ACID DERIVATIVES HAVING BRADYKININ RECEPTOR AFFINITY | SANOFI (FR) | 1997-07-17 | — | — | WO | disclosed |
| US-5591854-A | CATALYTIC CONDENSATION OF DIENES AND VINYLDIAZOMETHANEESTERS | WAKE FOREST UNIVERSITY (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996011928-A1 | ENANTIOSELECTIVE SYNTHESIS OF SEVEN-MEMBERED CARBOCYCLES AND TROPANES | WAKE FOREST UNIVERSITY (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | FKBP1A 3502/4885MMP8 4343/4885MMP12 4598/4885 |
| US-10093906-B2 | Cytochrome C protein variants for catalyzing carbon-silicon bond formation | CYC1, HCCS, COX6C | FKBP1A 55/4885MMP8 2424/4885MMP12 1603/4885 |
| US-10927355-B2 | Method for producing an organosilicon product | HMOX2, HMOX1, HMBS | FKBP1A 85/4885MMP8 1631/4885MMP12 1123/4885 |
| US-20180371430-A1 | Heme Protein Catalysts for Carbon-Silicon Bond Formation In Vitro and In Vivo | HMOX2, HMOX1, HCCS | FKBP1A 86/4885MMP8 1616/4885MMP12 867/4885 |
| US-20170218346-A1 | Heme Protein Catalysts for Carbon-Silicon Bond Formation In Vitro and In Vivo | HMOX2, HMOX1, HCCS | FKBP1A 86/4885MMP8 1616/4885MMP12 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.